IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
Investors 1
| Date | Name | Website |
| - | Gilde Heal... | gildehealt... |
Mentions in press and media 1
| Date | Title | Description |
| 07.05.2008 | IDEA AG receives two milestone payments ($37 million) from partner Alpharma | IDEA AG today announced that it has received two milestone payments under the US licensing agreement with Alpharma Ireland Limited for Diractin® (ketoprofen in Transfersome®, formerly known as IDEA-033). The total payment of $37 million was... |